Table 1

Characteristics of the population

RosiglitazoneMetforminSulfonylureaPioglitazone
n1,87912,49011,200806
Age*64.0 ± 11.461.7 ± 12.265.8 ± 12.163.7 ± 11.5
Female sex908 (48.3)6,628 (53.1)4,760 (42.5)384 (47.6)
Myocardial infarction outcome133 (7.1)406 (3.3)768 (6.9)36 (4.5)
Prior myocardial infarction234 (12.5)1,421 (11.4)1,945 (17.4)94 (11.7)
Prior cardiovascular disease597 (31.8)3,369 (27.0)4,544 (40.6)251 (31.1)
Hypertension1,689 (89.9)10,454 (83.7)10,076 (90.0)709 (88.0)
Hyperlipidemia1,466 (78.0)8,484 (67.9)7,545 (67.4)602 (74.7)
Chronic renal insufficiency (creatinine >2 mg/dl)338 (18.0)936 (7.5)2,374 (21.2)121 (15.0)
Outpatient insulin use446 (23.7)2,341 (18.7)1,425 (12.7)263 (32.6)
A1C8.0 ± 1.77.8 ± 1.77.7 ± 1.78.1 ± 1.8
Antihyperlipidemic medication use1,340 (71.3)7,721 (61.8)6,610 (59.0)556 (69.0)
    Combination35 (1.9)90 (0.7)80 (0.7)19 (2.4)
    Fibrates191 (10.2)887 (7.1)730 (6.5)86 (10.7)
    Statins1,287 (68.5)7,473 (59.8)6,428 (57.4)526 (65.3)
Antihypertensive medication use1,535 (81.7)9,358 (74.9)8,620 (77.0)649 (80.5)
    ACE inhibitors1,096 (58.3)7,019 (56.2)6,108 (54.5)463 (57.4)
    Angiotensin II antagonists406 (21.6)1,931 (15.5)1,697 (15.2)170 (21.1)
    β-Blockers1,033 (55.0)5,490 (44.0)6,138 (54.8)400 (49.6)
    Calcium channel blockers551 (29.3)2,783 (22.3)3,219 (28.7)204 (25.3)
    Combinations275 (14.6)1,844 (14.8)1,315 (11.7)123 (15.3)
    α-β163 (8.7)739 (5.9)1,068 (9.5)47 (5.8)
    Potassium-sparing diuretics5 (0.3)67 (0.5)73 (0.7)4 (0.5)
    Unclassified combinations10 (0.5)24 (0.2)17 (0.2)4 (0.5)
Age-adjusted Charlson score*7.9 ± 4.47.1 ± 4.28.5 ± 4.57.5 ± 4.2
  • Data are n (%) or means ± SD.

  • *Age at index date.